Marshall Wace LLP purchased a new stake in shares of Gritstone Oncology Inc (NASDAQ:GRTS) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 108,019 shares of the company’s stock, valued at approximately $1,436,000. Marshall Wace LLP owned approximately 0.30% of Gritstone Oncology as of its most recent SEC filing.
A number of other large investors have also modified their holdings of the stock. Citigroup Inc. acquired a new position in Gritstone Oncology in the fourth quarter worth about $28,000. American International Group Inc. acquired a new position in Gritstone Oncology in the fourth quarter worth about $70,000. D. E. Shaw & Co. Inc. acquired a new position in Gritstone Oncology in the fourth quarter worth about $157,000. Squarepoint Ops LLC bought a new stake in Gritstone Oncology during the fourth quarter worth about $444,000. Finally, Deutsche Bank AG bought a new stake in Gritstone Oncology during the fourth quarter worth about $448,000. Hedge funds and other institutional investors own 48.83% of the company’s stock.
GRTS stock traded down $0.11 during midday trading on Thursday, reaching $10.31. The company’s stock had a trading volume of 98,906 shares, compared to its average volume of 196,748. Gritstone Oncology Inc has a 52 week low of $8.75 and a 52 week high of $32.90. The stock has a market capitalization of $372.20 million and a PE ratio of -1.42. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.57 and a current ratio of 9.57. The stock’s 50-day moving average price is $10.40.
GRTS has been the topic of several research analyst reports. Cowen reaffirmed a “buy” rating on shares of Alector in a research note on Monday, May 13th. Zacks Investment Research cut shares of H&E Equipment Services from a “hold” rating to a “sell” rating in a research note on Wednesday. HC Wainwright reissued a “buy” rating and set a $26.00 price target on shares of Iovance Biotherapeutics in a research note on Monday, April 1st. Finally, Berenberg Bank decreased their price target on shares of Lucara Diamond from C$1.60 to C$1.50 in a research note on Wednesday, March 27th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $20.50.
Gritstone Oncology Profile
Gritstone Oncology Inc, an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers.
Featured Article: How are capital gains distributions different for tax-deferred account?
Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.